NuVasive, Inc. agreed to acquire SafePassage, a privately held provider of intraoperative neurophysiological monitoring services.
Terms of the deal were not disclosed. The transaction is expected to close in January 2018, subject to customary closing conditions.
NuVasive anticipates the deal will be accretive to its non-GAAP EPS in 2018 and beyond. It also expects the transaction to support its longer-term targets for revenue growth and expansion of its non-GAAP operating and EBITDA margins.
The transaction is also expected to meet the company's goals for return on invested capital for tuck-in acquisitions in three years.
